GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cosmo Bio Co Ltd (TSE:3386) » Definitions » LT-Debt-to-Total-Asset

Cosmo Bio Co (TSE:3386) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Cosmo Bio Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cosmo Bio Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Cosmo Bio Co's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).


Cosmo Bio Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Cosmo Bio Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Bio Co LT-Debt-to-Total-Asset Chart

Cosmo Bio Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cosmo Bio Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cosmo Bio Co LT-Debt-to-Total-Asset Calculation

Cosmo Bio Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/10872
=0.00

Cosmo Bio Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0/10872
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosmo Bio Co  (TSE:3386) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Cosmo Bio Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Cosmo Bio Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Bio Co (TSE:3386) Business Description

Traded in Other Exchanges
N/A
Address
2-20, Toyo-Ekimae Building, Toyo 2-Chome, Koto-ku, Tokyo, JPN, 135-0016
Cosmo Bio Co Ltd is a diagnostic and research company based in Japan. The business of the company includes purchase of reagents, instruments, clinical test drugs for research on life science and domestic sales.

Cosmo Bio Co (TSE:3386) Headlines

No Headlines